Tag
A new patient-level social determinants of health measure independently predicts advanced stage and survival outcomes in colon cancer patients, highlighting the importance of integrating social risk factors into oncologic care.
Postoperative day 2 C-reactive protein under 100 mg/L effectively excludes anastomotic leakage with high negative predictive value, enabling earlier and safer discharge in colon cancer resection patients within ERAS protocols.
A major randomized trial found that chemotherapy before surgery did not improve 3-year disease-free survival in locally advanced colon cancer, but it still revealed important clues for more personalized treatment.
A population-based study in England reveals that correcting socioeconomic and clinical inequalities in the use of minimally invasive surgery for colon cancer significantly reduces hospital stays and 1-year mortality, highlighting a critical
A post hoc analysis of CALGB (Alliance)/SWOG 80702 shows postoperative ctDNA positivity strongly predicts recurrence and suggests adjuvant celecoxib improves DFS and OS in ctDNA-positive stage III colon cancer.
The randomized phase 2/3 DYNAMIC-III trial shows that postoperative circulating tumor DNA (ctDNA) strongly stratifies recurrence risk in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations wi
The DYNAMIC-III trial validates circulating tumor DNA (ctDNA) as a strong prognostic marker in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations with near-standard outcomes, but escalation
A rigorous pooled analysis of over 35,000 patients identifies a recurrence risk below 0.5% at 6 years post-surgery, providing a practical benchmark for defining cure in stage II-III colon cancer and refining patient management strategies.
The SAKK 41/13 trial provides the first prospective randomized evidence that adjuvant aspirin may improve disease-free survival in patients with resected PIK3CA-mutated stage II and III colon cancer, suggesting its potential as a safe, cost
A 3-year structured exercise program post-adjuvant chemotherapy significantly improves disease-free and overall survival in colon cancer patients, based on the CHALLENGE phase 3 RCT involving 889 patients.
LBM-based oxaliplatin dosing significantly reduces peripheral neurotoxicity without compromising survival outcomes in adjuvant treatment for stage III colon cancer.
